The insulin-like growth factor system and cancer

Cancer Letters

Volumn 195, Issue 2, 2003, Pages 127-137

  LeRoith, Derek ^a   Roberts Jr , Charles T ^b  

^a Natl Institutes of Health MSC 1758   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Cancer; Insulin receptor; Insulin like growth factor

Indexed keywords

BINDING PROTEIN; INSULIN RECEPTOR; SOMATOMEDIN; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN;

APOPTOSIS; BREAST CANCER; CANCER; CANCER CELL; CANCER RISK; CANCER SURVIVAL; CELL ADHESION; CELL DEATH; CELL MIGRATION; CELL PROLIFERATION; COLON CANCER; DISEASE COURSE; EVIDENCE BASED MEDICINE; HORMONE ACTION; HUMAN; HYPOGLYCEMIA; LUNG CANCER; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; SHORT SURVEY; SIGNAL TRANSDUCTION; TARGET ORGAN;

EID: 0038398622     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(03)00159-9     Document Type: Review

References (66)

1. Baxter R.C. Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities. Am. J. Physiol. Endocrinol. Metab. 278:2000;E967-E976.
2. Clemmons D.R. Use of mutagenesis to probe IGF-binding protein structure/function relationships. Endocr. Rev. 22:2001;800-817.
3. LeRoith D., Werner H., Beitner-Johnson D., Roberts C.T. Jr. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr. Rev. 16:1995;143-163.
4. Daughaday W.H., Rotwein P. Insulin-like growth factors I and II: peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. Endocr. Rev. 10:1989;68-91.
5. Rother K.I., Accili D. Role of insulin receptors and IGF receptors in growth and development. Pediatr. Nephrol. 14:2000;558-561.
6. Frasca F., Pandini G., Scalia P., et al. Insulin receptor isoform A, a newly recognized, high-affinity insulin- like growth factor II receptor in fetal and cancer cells. Mol. Cell Biol. 19:1999;3278-3288.
7. Pandini G., Frasca F., Mineo R., Sciacca L., Vigneri R., Belfiore A. Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved. J. Biol. Chem. 277:2002;39684-39695.
8. White M.R. The IRS-1 signaling system. Curr. Opin. Genet. Dev. 4:1994;47-54.
9. Khandwala H.M., McCutcheon I.E., Flyvbjerg A., Friend K.E. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr. Rev. 21:2000;215-244.
10. Werner H., Karnieli E., Rauscher F.J., LeRoith D. Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. Proc. Natl Acad. Sci. USA. 93:1996;8318-8323.
11. Girnita L., Girnita A., Brodin B., et al. Increased expression of insulin-like growth factor I receptor in malignant cells expressing aberrant p53: functional impact. Cancer Res. 60:2000;5278-5283.
12. Tanno S., Mitsuuchi Y., Altomare D.A., Xiao G.H., Testa J.R. AKT activation up-regulates insulin-like growth factor I receptor expression and promotes invasiveness of human pancreatic cancer cells. Cancer Res. 61:2001;589-593.
13. Garrouste F., Remacle-Bonnet M., Fauriat C., Marvaldi J., Luis J., Pommier G. Prevention of cytokine-induced apoptosis by insulin-like growth factor-I is independent of cell adhesion molecules in HT29-D4 colon carcinoma cells-evidence for a NF-kappaB-dependent survival mechanism. Cell Death Differ. 9:2002;768-779.
14. Cheshire J.L., Baldwin A.S. Jr. Synergistic activation of NF-kappaB by tumor necrosis factor alpha and gamma interferon via enhanced I kappaB alpha degradation and de novo I kappaBbeta degradation. Mol. Cell Biol. 17:1997;6746-6754.
15. Andre F., Rigot V., Thimonier J., et al. Integrins and E-cadherin cooperate with IGF-I to induce migration of epithelial colonic cells. Int. J. Cancer. 83:1999;497-505.
16. Pennisi P.A., Barr V., Nunez N.P., Stannard B., LeRoith D. Reduced expression of insulin-like growth factor-I receptors in mcf-7 breast cancer cells leads to a more metastatic phenotype. Cancer Res. 62:2002;6529-6537.
17. Satyamoorthy K., Li G., Vaidya B., Patel D., Herlyn M. Insulin-like growth factor-1 induces survival and growth of biologically early melanoma cells through both the mitogen-activated protein kinase and beta-catenin pathways. Cancer Res. 61:2001;7318-7324.
18. Gilmore A.P., Valentijn A.J., Wang P., et al. Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor. J. Biol. Chem. 277:2002;27643-27650.
19. Dupont J., Karas M., LeRoith D. The potentiation of estrogen on insulin-like growth factor I action in MCF-7 human breast cancer cells includes cell cycle components. J. Biol. Chem. 275:2000;35893-35901.
20. Dalle S., Ricketts W., Imamura T., Vollenweider P., Olefsky J.M. Insulin and insulin-like growth factor I receptors utilize different G protein signaling components. J. Biol. Chem. 276:2001;15688-15695.
21. Chakravarti A., Loeffler J.S., Dyson N.J. Insulin-like growth factor receptor I mediates resistance to anti- epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res. 62:2002;200-207.
22. Meyer G.E., Shelde E., Kim B., Feldman E.L. Insulin-like growth factor I stimulates motility in human neuroblastoma cells. Oncogene. 20:2001;7542-7550.
23. Satyamoorthy K., Li G., Vaidya B., Kalabis J., Herlyn M. Insulin-like growth factor-I-induced migration of melanoma cells is mediated by interleukin-8 induction. Cell Growth Differ. 13:2002;87-93.
24. Reinmuth N., Liu W., Fan F., et al. Blockade of insulin-like growth factor I receptor function inhibits growth and angiogenesis of colon cancer. Clin. Cancer Res. 8:2002;3259-3269.
25. Scotlandi K., Avnet S., Benini S., et al. Expression of an IGF-I receptor dominant negative mutant induces apoptosis, inhibits tumorigenesis and enhances chemosensitivity in Ewing's sarcoma cells. Int. J. Cancer. 101:2002;11-16.
26. Pietrzkowski Z., Mulholland G., Gomella L., Jameson B.A., Wernicke D., Baserga R. Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor 1. Cancer Res. 53:1993;1102-1106.
27. D'Ambrosio C., Ferber A., Resnicoff M., Baserga R. A soluble insulin-like growth factor I receptor that induces apoptosis of tumor cells in vivo and inhibits tumorigenesis. Cancer Res. 56:1996;4013-4020.
28. Favelyukis S., Till J.H., Hubbard S.R., Miller W.T. Structure and autoregulation of the insulin-like growth factor 1 receptor kinase. Nat. Struct. Biol. 8:2001;1058-1063.
29. Munshi S., Kornienko M., Hall D.L., et al. Crystal structure of the Apo, unactivated insulin-like growth factor-1 receptor kinase: Implication for inhibitor specificity. J. Biol. Chem. 277:2002;38797-38802.
30. Pautsch A., Zoephel A., Ahorn H., Spevak W., Hauptmann R., Nar H. Crystal structure of bisphosphorylated IGF-1 receptor kinase: insight into domain movements upon kinase activation. Structure (Camb). 9:2001;955-965.
31. DeMeyts P., Whittaker J. Structural biology of insulin and IGF1 receptors: implications for drug design. Nat. Rev. Drug Discov. 1:2002;769-783.
32. Cohen P. Serum insulin-like growth factor-I levels and prostate cancer risk-interpreting the evidence. J. Natl Cancer Inst. 90:1998;876-879.
33. Wolk A., Mantzoros C.S., Andersson S.O., et al. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J. Natl Cancer Inst. 90:1998;911-915.
34. Cohen P., Peehl D.M., Baker B., Liu F., Hintz R.L., Rosenfeld R.G. Insulin-like growth factor axis abnormalities in prostatic stromal cells from patients with benign prostatic hyperplasia. J. Clin. Endocrinol. Metab. 79:1994;1410-1415.
35. Cohen P., Peehl D.M., Rosenfeld R.G. The IGF axis in the prostate. Horm. Metab. Res. 26:1994;81-84.
36. Cohen P., Peehl D.M., Graves H.C., Rosenfeld R.G. Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease. J. Endocrinol. 142:1994;407-415.
37. Torring N., Vinter-Jensen L., Pedersen S.B., Sorensen F.B., Flyvbjerg A., Nexo E. Systemic administration of insulin-like growth factor I (IGF-I) causes growth of the rat prostate. J. Urol. 158:1997;222-227.
38. Huynh H., Seyam R.M., Brock G.B. Reduction of ventral prostate weight by finasteride is associated with suppression of insulin-like growth factor I (IGF-I) and IGF-I receptor genes and with an increase in IGF binding protein 3. Cancer Res. 58:1998;215-218.
39. Ruan W., Powell-Braxton L., Kopchick J.J., Kleinberg D.L. Evidence that insulin-like growth factor I and growth hormone are required for prostate gland development. Endocrinology. 140:1999;1984-1989.
40. Cutting C.W., Hunt C., Nisbet J.A., Bland J.M., Dalgleish A.G., Kirby R.S. Serum insulin-like growth factor-1 is not a useful marker of prostate cancer. BJU Int. 83:1999;996-999.
41. Djavan B., Bursa B., Seitz C., et al. Insulin-like growth factor 1 (IGF-1), IGF-1 density, and IGF-1/PSA ratio for prostate cancer detection. Urology. 54:1999;603-606.
42. Finne P., Auvinen A., Koistinen H., et al. Insulin-like growth factor I is not a useful marker of prostate cancer in men with elevated levels of prostate-specific antigen. J. Clin. Endocrinol. Metab. 85:2000;2744-2747.
43. Baffa R., Reiss K., El-Gabry E.A., et al. Low serum insulin-like growth factor 1 (IGF-1): a significant association with prostate cancer. Tech. Urol. 6:2000;236-239.
44. Harman S.M., Metter E.J., Blackman M.R., Landis P.K., Carter H.B. Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer. J. Clin. Endocrinol. Metab. 85:2000;4258-4265.
45. Stattin P., Bylund A., Rinaldi S., et al. Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. J. Natl Cancer Inst. 92:2000;1910-1917.
46. Hankinson S.E., Willett W.C., Colditz G.A., et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet. 351:1998;1393-1396.
47. Vadgama J.V., Wu Y., Datta G., Khan H., Chillar R. Plasma insulin-like growth factor-I and serum IGF-binding protein 3 can be associated with the progression of breast cancer, and predict the risk of recurrence and the probability of survival in African-American and Hispanic women. Oncology. 57:1999;330-340.
48. Jernstrom H., Barrett-Connor E. Obesity, weight change, fasting insulin, proinsulin, C-peptide, and insulin-like growth factor-1 levels in women with and without breast cancer: the Rancho Bernardo Study. J. Womens Health Gend. Based Med. 8:1999;1265-1272.
49. Agurs-Collins T., Adams-Campbell L.L., Kim K.S., Cullen K.J. Insulin-like growth factor-1 and breast cancer risk in postmenopausal African-American women. Cancer Detect Prev. 24:2000;199-206.
50. Ma J., Pollak M.N., Giovannucci E., et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J. Natl Cancer Inst. 91:1999;620-625.
51. Palmqvist R., Hallmans G., Rinaldi S., et al. Plasma insulin-like growth factor 1, insulin-like growth factor binding protein 3, and risk of colorectal cancer: a prospective study in northern Sweden. Gut. 50:2002;642-646.
52. Probst-Hensch N.M., Yuan J.M., Stanczyk F.Z., Gao Y.T., Ross R.K., Yu M.C. IGF-1, IGF-2 and IGFBP-3 in prediagnostic serum: association with colorectal cancer in a cohort of Chinese men in Shanghai. Br. J. Cancer. 85:2001;1695-1699.
53. Yu H., Spitz M.R., Mistry J., Gu J., Hong W.K., Wu X. Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J. Natl Cancer Inst. 91:1999;151-156.
54. Lukanova A., Toniolo P., Akhmedkhanov A., prospective A., et al. study of insulin-like growth factor-I, IGF-binding proteins-1, -2 and -3 and lung cancer risk in women. Int. J. Cancer. 92:2001;888-892.
55. Almeida A., Muleris M., Dutrillaux B., Malfoy B. The insulin-like growth factor I receptor gene is the target for the 15q26 amplicon in breast cancer. Genes Chromosomes Cancer. 11:1994;63-65.
56. DePinho R.A. The age of cancer. Nature. 408:2000;248-254.
57. Kaleko M., Rutter W.J., Miller A.D. Overexpression of the human insulinlike growth factor I receptor promotes ligand-dependent neoplastic transformation. Mol. Cell Biol. 10:1990;464-473.
58. Turner B.C., Haffty B.G., Narayanan L., et al. Glazer insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res. 57:1997;3079-3083.
59. Wen B., Deutsch E., Marangoni E., et al. Tyrphostin AG 1024 modulates radiosensitivity in human breast cancer cells. Br. J. Cancer. 85:2001;2017-2021.
60. Tennant M.K., Thrasher J.B., Twomey P.A., Drivdahl R.H., Birnbaum R.S., Plymate S.R. Protein and messenger ribonucleic acid (mRNA) for the type 1 insulin-like growth factor (IGF) receptor is decreased and IGF-II mRNA is increased in human prostate carcinoma compared to benign prostate epithelium. J. Clin. Endocrinol. Metab. 81:1996;3774-3782.
61. Happerfield L.C., Miles D.W., Barnes D.M., Thomsen L.L., Smith P., Hanby A. The localization of the insulin-like growth factor receptor 1 (IGFR-1) in benign and malignant breast tissue. J. Pathol. 183:1997;412-417.
62. Chott A., Sun Z., Morganstern D., et al. Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptor. Am. J. Pathol. 155:1999;1271-1279.
63. Schnarr B., Strunz K., Ohsam J., Benner A., Wacker J., Mayer D. Down-regulation of insulin-like growth factor-I receptor and insulin receptor substrate-1 expression in advanced human breast cancer. Int. J. Cancer. 89:2000;506-513.
64. Damon S.E., Plymate S.R., Carroll J.M., et al. Transcriptional regulation of insulin-like growth factor-I receptor gene expression in prostate cancer cells. Endocrinology. 142:2001;21-27.
65. Hellawell G.O., Turner G.D., Davies D.R., Poulsom R., Brewster S.F., Macaulay V.M. Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res. 62:2002;2942-2950.
66. Sperandio S., deBelle I., Bredesen D.E. An alternative, nonapoptotic form of programmed cell death. Proc. Natl Acad. Sci USA. 97:2002;14376-14381.